The drug is intended to treat myopic choroidal neovascularization, a condition that can lead to vision loss or blindness.
The priority review process, which expedites the review of a drug application to about six months after filing, was created to decrease the time it takes to put new medicines on the market.
If approved, San Francisco-based Genentech would maintain all commercial rights to Lucentis in the U.S., while Roche would hold commercial rights outside the U.S.
More articles on supply chain:
St. Jude Medical issues warning on heart device after 2 patient deaths
Cost is king: 5 thoughts on the hospital supply chain from an expert who’s seen both sides of the business
Red Cross stresses need for blood, platelets after hurricane cancels 40 blood drives
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
